Summary
The TARGET of IPGA06 is an immunosuppressive cytokine involved in tumour immune escape by inducing regulatory T cells (Tregs), tumor-associated macrophages (TAMs), tolerogenic DCs (tolDCs), and B cells with regulatory properties (Bregs). The target can expand regulatory responses and promote immune tolerance. It suppresses the proliferation and function of effector T cells within the tumor microenvironment (TME). Therefore, targeted neutralization of the IPGA06 represents a potential therapeutic approach against cancer. IPGA06 is a promising first-in-class neutralizing antibody that can block the accumulation of Tregs induced by the target in the TME.
Mechanism of Action
￭ Neutralization of the IPGA06 target.
￭ Reduction in the population of Tregs.
￭ Promotion of activated CD8+ T cells in cancer treatment.
Cpyright © 2023 Nanjing Immunophage Biotech Co.,Ltd
All Rights Reserved. 苏ICP备2022026466号-1 
苏公网安备 32011202000830号
Back